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A B S T R A C T
Background
Recurrent urinary tract infections (RUTI) are common in women who are pregnant and may cause serious adverse pregnancy outcomes
for both mother and child including preterm birth and small-for-gestational-age babies. Interventions used to prevent RUTI in women
who are pregnant can be pharmacological (antibiotics) or non-pharmacological (cranberry products, acupuncture, probiotics and
behavioural modifications). So far little is known about the best way to prevent RUTI in pregnant women.
Objectives
To assess the effects of interventions for preventing RUTI in pregnant women.
The primary maternal outcomes were RUTI before birth (variously defined) and preterm birth (before 37 weeks). The primary infant
outcomes were small-for-gestational age and total mortality.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (20 May 2015) and reference lists of retrieved articles.
Selection criteria
Published, unpublished and ongoing randomised controlled trials (RCTs), quasi-RCTs, clustered-randomised trials and abstracts of any
intervention (pharmacological and non-pharmacological) for preventing RUTI during pregnancy (compared with another intervention,
placebo or with usual care).
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.
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Main results
The review included one trial involving 200 women and was at moderate to high risk of bias.The trial compared a daily dose of
nitrofurantoin and close surveillance (regular clinic visit, urine cultures and antibiotics when a positive culture was found) with close
surveillance only. No significant differences were found for the primary outcomes: recurrent pyelonephritis (risk ratio (RR) 0.89, 95%
confidence interval (CI) 0.31 to 2.53; one study, 167 women), RUTI before birth (RR 0.30, 95% CI 0.06 to 1.38; one study, 167
women), and preterm birth (before 37 weeks) (RR 1.18, 95% CI 0.42 to 3.35; one study, 147 women). The overall quality of evidence
for these outcomes as assessed using GRADE was very low. There were no significant differences between the two comparison groups
for any of the following secondary outcomes, birthweight less than 2500 (g) (RR 2.03, 95% CI 0.53 to 7.80; one study, 147 infants),
birthweight (mean difference (MD) -113.00, 95% CI -327.20 to 101.20; one study, 147 infants), five-minute Apgar score less than
seven (RR 2.03, 95% CI 0.19 to 21.87; one study, 147 infants) and miscarriages (RR 3.11, 95% CI 0.33 to 29.29; one study, 167
women). The evidence for these secondary outcomes was also of very low quality. The incidence of asymptomatic bacteriuria (ASB) (at
least 103 colonies per mL) (secondary outcome), only reported in women with a clinic attendance rate of more than 90% (RR 0.55,
95% CI 0.34 to 0.89; one study, 102 women), was significantly reduced in women who received nitrofurantoin and close surveillance.
Data on total mortality and small-for-gestational-age babies were not reported.
Authors’ conclusions
A daily dose of nitrofurantoin and close surveillance has not been shown to prevent RUTI compared with close surveillance alone.
A significant reduction of ASB was found in women with a high clinic attendance rate and who received nitrofurantoin and close
surveillance. There was limited reporting of both primary and secondary outcomes for both women and infants. No conclusions can
be drawn regarding the optimal intervention to prevent RUTI in women who are pregnant. Randomised controlled trials comparing
different pharmacological and non-pharmacological interventions are necessary to investigate potentially effective interventions to
prevent RUTI in women who are pregnant.
P L A I N L A N G U A G E S U M M A R Y
Interventions for preventing recurrent urinary tract infections during pregnancy
Recurrent urinary tract infections (RUTI) are common in women generally, and particularly in pregnant women. A urinary tract
infection (UTI) is an infection of the urinary tract (bladder, kidneys) due to the presence of bacteria in the urine (bacteriuria). During
pregnancy, UTI may be a serious complication that is associated with adverse pregnancy outcomes for both mother and child including
preterm birth and small-for-gestational-age babies. Therefore, it is important to define the optimal intervention for preventing RUTI
during pregnancy to improve pregnancy outcomes. Interventions used to prevent RUTI in pregnant women can be pharmacological
(antibiotics) or non-pharmacological (cranberry products, acupuncture, probiotics and behavioural modifications). So far, little is
known about the best way to prevent RUTI in pregnant women.
This review identified one study involving 200 pregnant women who received nitrofurantoin (antibiotics) and close surveillance (regular
clinic visit, urine cultures and antibiotics when a positive culture was found) or close surveillance alone. Suppressive therapy with
daily dose of nitrofurantoin and close surveillance was not shown to prevent RUTI compared with close surveillance alone but the
evidence was of very low quality. A significant reduction of asymptomatic bacteriuria (presence of bacteria in the urine without the
symptoms of a UTI) was found in women with a high clinic attendance rate who received nitrofurantoin and close surveillance. Due
to lack of evidence no conclusions can be drawn. Future randomised controlled trials comparing different pharmacological and non-
pharmacological interventions are necessary to assess the optimal intervention to prevent RUTI in women who are pregnant. Such
trials should report on a comprehensive range of outcomes for both women and infants.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nitrofurantoin and close surveillance compared with close surveillance alone for preventing recurrent urinary tract infection during pregnancy
Patient or population: pregnant women with a history of one or more UTI before or during pregnancy
Settings: Los Angeles, USA.
Intervention: nitrofurantoin and close surveillance
Comparison: close surveillance alone
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82 per 1000 73 per 1000
(26 to 208)
Moderate
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81 per 1000 96 per 1000
(34 to 272)
Moderate
81 per 1000 96 per 1000
(34 to 272)






41 per 1000 82 per 1000
(21 to 316)
Moderate
41 per 1000 82 per 1000
(21 to 316)
Birthweight (g) The mean birthweight
(g) in the control group
was 0
The mean birthweight
(g) in the intervent ion
group was 113 lower














14 per 1000 27 per 1000
(3 to 296)
Moderate




















































































































12 per 1000 37 per 1000
(4 to 345)
Moderate
12 per 1000 37 per 1000
(4 to 346)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1One study with design lim itat ions (-1)
2One study of small sample size and few events. Wide CI crossing the line of no ef fect (-2)
3One study of small sample size. Wide CI (-1)













































































































B A C K G R O U N D
Description of the condition
Recurrent urinary tract infections (RUTI) are a common health-
care problem in women generally and particularly in pregnant
women. Up to 30% of women who are not pregnant experience
at least one recurrence within a year after the initial infection
(Foxman 1990; Hooton 2001; Mabeck 1972; Scholes 2000). A
urinary tract infection (UTI) is an infection of the urinary tract
which can be divided in lower and upper UTI based on the lo-
cation of the infection. A lower UTI is an infection of the blad-
der and results in a combination of significant bacteriuria and
symptoms such as dysuria (painful urination) and frequency. In
practice the diagnosis of UTI is often based on clinical symptoms
alone. An upper UTI or pyelonephritis is an infection of the kid-
ney accompanied by symptoms such as fever and renal tenderness.
Asymptomatic bacteriuria (ASB) is significant bacteriuria without
symptoms of a UTI (Schnarr 2008; Sobel 2014).
A UTI during pregnancy may be a serious complication as it
is associated with adverse pregnancy outcomes for both mother
and child (Anderson 2007; Bánhidy 2007; Dimetry 2007; Savage
1967; Schieve 1994; Sheiner 2009; Vazquez 2011). Important
complications include preterm birth and small-for-gestational-age
babies (Dimetry 2007; Lang 1996; Mazor-Dray 2009), although
an association between UTI and preterm birth and small-for-ges-
tational-age babies has not been clearly established (Bánhidy 2007;
Chen 2010; Dimetry 2007; Mann 2009; Mazor-Dray 2009). As-
sociations seen between UTI and adverse pregnancy outcomes in
older studies (before the 1970s) may no longer be as evident with
the advent of more antibiotic prescriptions (Bánhidy 2007; Savage
1967). While causal mechanisms remain unknown, there is evi-
dence supporting the important role that prostaglandins, stimu-
lated by bacterial and host signals following an infection, play in
inducing preterm labour (Olson 2003; Romero 1988).
The exact incidence of symptomatic UTI in women who are preg-
nant is unknown (Gilstrap 2001). Two studies report an incidence
between 1% to 2.3% during pregnancy for their particular pop-
ulation (Harris 1981; Mazor-Dray 2009). Pyelonephritis (infec-
tion of the kidney) occurs in 2% of pregnancies, with a recurrence
rate up to 23% within the same pregnancy or soon after the birth
(Gilstrap 1981; McCormick 2008).
Some international guidelines recommend screening and treating
ASB in women who are pregnant to prevent UTI and possible
adverse pregnancy outcomes (U.S. Preventive Services Task Force
2008). This policy is followed by many countries and might have
had an impact on the recently described incidences of both UTI
and RUTI during pregnancy.
Varying definitions of RUTI exist, especially in pregnant women.
In non-pregnant women RUTI is frequently defined as three
episodes of UTI in the previous 12 months, or two episodes in the
last six months (Epp 2010; Foster 2008; Gopal 2007). For this
review we used the following criteria for RUTI: pregnant women
with a history of one or more UTI before or during pregnancy. We
decided to include women with only one UTI as well because one
UTI during pregnancy can be a reason to start prophylaxis during
pregnancy both in practice and for research trials. Most UTI re-
currences occur in the first three months following the initial in-
fection (Foxman 1990). In studies on RUTI in pregnant women,
one episode of UTI during pregnancy is often an indication to
start prophylaxis to prevent RUTI (Harris 1974; Pfau 1992).
Uropathogens, generally originating in the rectal flora, may cause
a UTI when they ascend to the bladder after they colonise the
urethra and the periurethral area. The pathogenesis of a UTI in
women who are suffering from RUTI is considered compara-
ble with a single infection in women without a history of RUTI
(Hooton 2010; Kodner 2010). In RUTI, uropathogens possibly
recolonise the bladder after treatment because they are not elim-
inated from the rectal flora (Hooton 2001). E. coli is the most
common UTI uropathogen (Kodner 2010; Sobel 2014). Partic-
ularly in the presence of structural abnormalities of the urinary
tract, the following organisms are associated with RUTI: Proteus,
Pseudomonas, Klebsiella and by Enterobacter spp. and enterococci
and staphylococci (Sobel 2014).
There are four patterns of response of bacteriuria to therapy: cure,
bacteriologic persistence, bacteriologic relapse or reinfection. Bac-
teriologic persistence is persistence of bacteriuria with the same
microorganism after 48 hours of treatment (Sobel 2014). Relapse
is an infection with the same microorganism that caused initial
infection and usually occurs within one to two weeks after the ces-
sation of treatment. A relapse indicates that the infecting organism
has persisted in the urinary tract. Reinfection is an infection after
sterilisation of the urine. Most of the time there is a change in
bacterial species. Reinfection can be defined as a ’true’ recurrence.
Both persistence and relapse may be related to inadequate treat-
ment (Hooton 2010; Sobel 2014). Although relapse and reinfec-
tion are two distinct outcomes, they both can be grouped under
the wider outcome of recurrence.
During pregnancy, up to 90% of the women develop dilatation
of the collecting system (ureters and renal pelvis) and decreased
peristalsis of the ureters and bladder, which may facilitate bacterial
colonisation and ascending infection due to urinary stasis (Brown
1991; Grenier 2000; McCormick 2008).
The main risk factors for RUTI in premenopausal women are: the
age at first UTI (less than 15 years of age indicates a greater risk
of RUTI), a family history of UTI in their mother, frequency of
sexual intercourse, the use of spermicides and new sexual partners
(Hooton 1996; Hooton 2001; Perotta 2008; Scholes 2000). In
women who are pregnant, a high parity is a risk factor for UTI
(Dwyer 2002; Haider 2010).
Description of the intervention
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Interventions used to prevent RUTI in pregnant women can be
pharmacological or non-pharmacological. Pharmacological inter-
ventions consist of antibiotics that may be prescribed in different
ways to prevent RUTI, continuous prophylaxis, post-coital pro-
phylaxis and patient-initiated therapy based on symptoms of a
UTI. The non-pharmacological interventions include cranberries
(juice or tablets), probiotics, acupuncture and behavioural modi-
fications such as frequent and complete voiding, voiding after sex-
ual intercourse, liberal fluid intake, and wiping techniques. Other
potential interventions, such as vaccines and bacterial interference
where one bacterial strain prevents colonisationwith another strain
and topical application of carbohydrates, are still under develop-
ment (Epp 2010).
How the intervention might work
Various antibiotic regimens, used as a continuous or as post-coital
prophylaxis, reduce the number of RUTI in women who are not
pregnant (Albert 2008; Hooton 2010; Pfau 1992). The effect of
post-coital prophylaxis is related to frequency of sexual intercourse
and mostly results in less antibiotic use in comparison with daily
prophylaxis (Hooton 2001; Hooton 2010). Antibiotics may cause
adverse effects such gastrointestinal symptoms and vaginal and
oral candidiasis (Albert 2008; Epp 2010). Furthermore, not all
antibiotics used as prophylaxis for RUTI in non-pregnant women
may be safe during pregnancy. Because of this, women who are
pregnant often prefer not to use antibiotics during their pregnancy.
In addition, the number of drug-resistant bacteria is increasing,
which may influence the potential prophylactic effect of different
antibiotics in the future. Different antibiotics such as nitrofuran-
toin, amoxicillin and fosfomycin have been used to treat primary
UTI inwomenwho are pregnant (Vazquez 2011). Antibiotic effect
depends on the concentration of the antimicrobial agent achieved
in the urine in conjunction with the sensitivity of the organism(s)
to that antibiotic (Sobel 2014).
Cranberry products (mainly juice) have been used as an interven-
tion to prevent RUTI for decades. It has been shown in vitro that
cranberries prevent bacteria adhering to the uro-epithelial cells in
the bladder (Jepson 2012; Zafiri 1989).Without adhesion the bac-
teria are unable to cause aUTI (Jepson 2012; Zafiri 1989). In some
of the published studies on cranberries in pregnant and non-preg-
nant women, there have been significant withdrawals or losses to
follow-up (Jepson 2012). Nausea and vomiting due to physiologic
changes in pregnancy can further decrease adherence (Wing 2008).
A trial in non-pregnant premenopausal women showed that an-
tibiotics (trimethoprim-sulfamethoxazole) once daily is more ef-
fective in preventing RUTI than cranberry capsules twice daily, at
the expense of emerging antibiotic resistance (Beerepoot 2011).
Finally a recent cochrane review on ’Cranberries for preventing uri-
nary tract infections’ that included two studies in pregnant women
concluded that more studies to assess the effectiveness of cran-
berry juice need ‘strong justification’ since the benefit is likely to
be small especially in combination with poor adherence. Only in
women with RUTI more studies of other cranberry products such
as tablets and capsules may be useful (Jepson 2012).
Two small randomised controlled trials (with unclear risk of se-
lection bias) have compared acupuncture with no treatment to
prevent RUTI in women who are not pregnant. Both showed sig-
nificant results in preventing RUTI (Alreak 2002; Aune 1998).
It is suggested that some Lactobacillus species prevent uropathogen
colonisation of the vagina, a necessary step in ascending infection
of the bladder. Studies show that certain Lactobacillus species can
be given orally or vaginally and reduce RUTI through colonisation
of the vagina and reducing vaginal coliform counts (Czaja 2007;
Reid 2003). In postmenopausal women the use of lactobacilli cap-
sules twice daily seems nearly as effective in preventing RUTI as
the use of antibiotics once daily, without increase of antibiotic re-
sistance (Beerepoot 2012).
Although behavioural modifications are unlikely to be harmful in
women who are not pregnant, little information is available that
these interventions actually work. Sexually active women who use
spermicide while suffering from RUTI are recommended to use
an alternative form of contraception (Epp 2010). Spermicide use
increases the risk of colonisation of the vaginal and periurethral
area with uropathogens and increases the adherence of E. coli to
vaginal epithelial cells (Sobel 2014). Behavioural modifications
may often be combined with other interventions (Epp 2010).
Why it is important to do this review
There are two Cochrane reviews on prevention of UTI, both in
women. (Albert 2008; Jepson 2012). One of these reviews in-
cluded two studies in pregnant women (Jepson 2012). The re-
sults described in the Cochrane review ’Antibiotics for preventing
recurrent urinary tract infections in non-pregnant women’ show that
continuous antibiotic prophylaxis for six to 12 months reduced
the rate of UTI during prophylaxis when compared with placebo.
However, women who used antibiotic prophylaxis had more ad-
verse effects (Albert 2008). The results described in the updated
Cochrane review ’Cranberries for preventing urinary tract infections’
demonstrate that cranberry juice was not as effective as previ-
ously indicated and did not decrease the number of symptomatic
UTIs over a 12-month period. Besides, the authors conclude that
cranberry juice may not be acceptable over long periods of time
because there were large numbers of dropouts (Jepson 2012). A
Cochrane protocol on ’Probiotics for preventing urinary tract infec-
tions in adults and children’ will include studies in women who are
pregnant (Schwenger 2010).
Preterm birth, one of the possible serious complications of a UTI
duringpregnancy, is themain cause of neonatalmortality andmor-
bidity worldwide. The costs of preterm birth are enormous. These
costs are mainly associated with intensive care for the neonates
(Armstrong 2007; Clements 2007; Gilbert 2003). Prevention of
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RUTI and UTI will improve maternal and infant health and re-
duce the risk of preterm birth.
Different approaches have been proposed for prevention of RUTI
in women who are not pregnant and include the use of low-
dose antibiotic prophylaxis daily or post-coitally in sexually active
women and non-pharmacological therapies such as voiding after
sexual intercourse or ingestion of cranberry juice (Albert 2008).
Little is known about the best way to prevent RUTI in preg-
nant women, especially as not all approaches used in non-preg-
nant women are applicable. Therefore, it is important to define
the optimal interventions for preventing RUTI during pregnancy
to improve pregnancy outcomes.
O B J E C T I V E S
To assess the effects of interventions for preventing recurrent uri-
nary tract infections in pregnant women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include all published, unpublished and ongoing
randomised controlled trials (RCTs), quasi-RCTs and clustered-
randomised trials of interventions aimed at preventing recurrent
urinary tract infections (RUTI) during pregnancy. In future up-
dates we will also include abstracts where sufficient information is
available. Abstracts containing limited information will be classi-
fied as ’awaiting assessment’ until further information can be ob-
tained.
Types of participants
Pregnant women with a history of one or more urinary tract in-
fections (UTI) before or during pregnancy.
Types of interventions
Any intervention (pharmacological and non-pharmacological) for
preventing recurrent urinary tract infection (RUTI) during preg-
nancy (compared with another intervention, placebo or with usual
care).
Types of outcome measures
Primary outcomes
Maternal
• RUTI before birth (variously defined e.g. recurrent
pyelonephritis, recurrent cystitis)
• Preterm birth (less than 37 weeks)
Infant
• Small-for-gestational age
• Total mortality (including stillbirth and babies born alive
who die prior to primary hospital discharge)
Secondary outcomes
Recurrences
• Proportion of pregnant women who experienced at least
one UTI, identified using clinical criteria (dysuria)
• Proportion of pregnant women who experienced at least
one UTI, using microbiological criteria
• Number of UTI per woman during index pregnancy,
identified using clinical criteria (e.g. dysuria, fever)
• Number of UTI per woman during index pregnancy, using
microbiological criteria
• Number of pregnant women who were admitted
antenatally because of a UTI




• Antenatal pyrexia requiring the use of antibiotics
• Asymptomatic bacteriuria (ASB) (variously defined)
• Prelabour rupture of the membranes
• Eclampsia/pre-eclampsia (variously defined)
• Induction of labour
• Mode of birth (normal vaginal birth, operative vaginal
birth, caesarean section)
• Intrapartum fever requiring the use of antibiotics
• Postpartum infection requiring the use of antibiotics
• Postpartum haemorrhage
• Chorioamnionitis (variously defined)
• Postpartum fever requiring the use of antibiotics
• Adverse effects of interventions (nausea, vomiting,
diarrhoea)
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• Proportion of women who had severe adverse effects
(defined as those requiring withdrawal of treatment)
• Women’s satisfaction with treatment
Infants
• Stillbirths (variously defined)
• Death of liveborn infants prior to hospital discharge
• Gestational age at birth
• Preterm birth less than 34 weeks’ gestation
• Birthweight
• Birthweight < 2500 (g) (not prespecified)
• Birth centile (below 10th centile)
• Small-for-gestational age
• Five-minute Apgar score less than seven
• Chronic lung disease (variously defined)
• Intraventricular haemorrhage (variously defined)
• Periventricular leukomalacia
• Necrotising enterocolitis (variously defined)
• Respiratory distress syndrome (variously defined)
• Hyperbilirubinaemia requiring treatment
• Neonatal convulsions
• Early neonatal infection requiring antibiotics (less than 48
hours)
• Hypoxic ischaemic encephalopathy
• Neonatal encephalopathy
• Composite of severe neonatal morbidity (variously defined)
Use of resources, e.g. and/or costs utilisation
• Antenatal admission of the mother
• Days of antenatal admission of the mother
• Admission to a neonatal intensive care unit
• Days of admission to a neonatal intensive care unit
• Admission to nursery care
• Costs of interventions
• Additional visits to clinicians
• Costs to women and families for extra care
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (20 May
2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
In addition, we searched the reference lists of retrieved articles We
did not apply any language or date restrictions to the search and
in future updates, we will attempt to obtain translations of papers
when necessary.
Data collection and analysis
For methods used in the previous version of this review, see
Schneeberger 2012.
Assessment of the quality of the evidence
For this update, no new reports were identified for assessment
but we assessed the quality of evidence of the existing study using
the GRADE approach (Schunemann 2009) in order to assess the
quality of the body of evidence relating to the following outcomes
for the comparison ’nitrofurantoin and close surveillance versus
close surveillance alone’.
1. Recurrent pyelonephritis
2. Recurrent UTI (cystitis)
3. Preterm birth (≤ 37 weeks)
4. Birthweight < 2500 (g)
5. Birthweight (g)
6. Five-minute Apgar score less than seven
7. Miscarriages
We used GRADEprofiler (GRADEpro 2014) to import data from
Review Manager 5.3 (RevMan 2014) in order to create a ’Sum-
mary of findings’ table. A summary of the intervention effect and
a measure of quality for each of the above outcomes has been pro-
duced using the GRADE approach. The GRADE approach uses
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five considerations (study limitations, consistency of effect, impre-
cision, indirectness and publication bias) to assess the quality of
the body of evidence for each outcome. The evidence was down-
graded from ’high quality’ by one level for serious (or by two levels
for very serious) limitations, depending on assessments for risk of
bias, indirectness of evidence, serious inconsistency, imprecision
of effect estimates or potential publication bias.
In future updates, if new reports are identified, we will use the
methods described in Appendix 1.
R E S U L T S
Description of studies
Results of the search
The search of the Cochrane Pregnancy and Childbirth Group’s
Trials Register retrieved two reports relating to one trial eligible
for consideration. This trial (involving 200 women) was included
in the review (Lenke 1983).
Included studies
Only one trial, performed in Los Angeles, USA with 200 preg-
nant women was identified that met the inclusion criteria (Lenke
1983). In this study, nitrofurantoin 50 mg three times daily and
close surveillance (regular clinic visit, urine cultures and antibi-
otics when a positive culture was found) was compared with
close surveillance only to prevent recurrent urinary tract infec-
tions (RUTI) in women who were pregnant and were admitted for
pyelonephritis earlier during the index pregnancy. Close surveil-
lance consisted of a visit every two weeks to a special clinic and
after 36 weeks, a weekly visit until birth. At each visit a clean-
catch, mid voided urine was obtained for a routine culture and
nitrite testing. When necessary, treatment was provided.
Excluded studies
There are no excluded studies.
Risk of bias in included studies
See Figure 1 and Figure 2 for a summary of the ’Risk of bias’
assessment.
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Figure 1. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
In the one included study (Lenke 1983), a random number table
was used to generate the sequence, which we considered a low risk
of bias. The method of treatment allocation was unclear.
Blinding
No placebos were used and the care providers and the participants
were not blinded. The ’Risk of bias’ assessment was considered
low for the culture results and delivery outcomes. Overall, we
considered the risk of bias for performance and detection bias to
be unclear.
Incomplete outcome data
There were 18 post-randomisation losses to follow-up in the nitro-
furantoin and close surveillance group and 15 in close surveillance
only group. No data about post randomisation data exclusions
were reported. The outcome birthweight of infants was not avail-
able for 11 (13.4%) women in the nitrofurantoin group and close
surveillance and for nine (10.6%) in the close surveillance only
group. The outcomes of birthweight < 2500 (g), preterm birth
(before 37 weeks) and five-minute Apgar score less than sevenwere
not available in nine (11.0%) of the women who received nitrofu-
rantoin and close surveillance and 11 (12.9%) of the women who
received close surveillance only.
Selective reporting
No data were reported on the following primary outcomes: to-
tal infant mortality and small-for-gestational-age babies. Further-
more, only a small number of secondary outcomes were reported.
Overall, we considered this domain to have a high risk of bias.
Other potential sources of bias
No obvious risk of other potential sources of bias for the included
studies was apparent.
Effects of interventions
See: Summary of findings for the main comparison
Nitrofurantoin and close surveillance compared with close
surveillance alone for preventing recurrent urinary tract infection
during pregnancy
This review included one trial (Lenke 1983) involving 200women.
Nitrofurantoin and close surveillance versus close
surveillance alone
Primary outcomes
Lenke 1983 found no differences in women who developed recur-
rent pyelonephritis (upper UTI) (risk ratio (RR) 0.89, 95% confi-
dence interval (CI) 0.31 to 2.53; one study, 167 women) (Analysis
1.1), or RUTI before birth (RR 0.30, 95% CI 0.06 to 1.38; one
study, 167 women) (Analysis 1.2), and preterm birth (before 37
weeks) (RR 1.18, 95% CI 0.42 to 3.35; one study, 147 women)
(Analysis 1.3) between nitrofurantoin and close surveillance and
close surveillance only. Data on total mortality and small-for-ges-
tational-age babies were not reported.
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Secondary outcomes
The only secondary outcomes reported were birthweight less than
2500 (g) (RR 2.03, 95% CI 0.53 to 7.80; one study, 147 infants)
(Analysis 1.4), birthweight (mean difference (MD) -113.00, 95%
CI -327.20 to 101.20; one study, 147 infants) (Analysis 1.5), five-
minute Apgar score less than seven (RR 2.03, 95% CI 0.19 to
21.87; one study, 147 infants) (Analysis 1.6), andmiscarriages (RR
3.11, 95% CI 0.33 to 29.29; one study, 167 women) (Analysis
1.7). There were no significant differences between the two com-
parison groups for any of these outcomes.
In women who received nitrofurantoin and close surveillance, the
incidence of ASB defined as positive cultures with at least 103
colonies per mL is only reported in women with more than 90%
clinic attendance rate (RR 0.55, 95% CI 0.34 to 0.89; one study,
102 women) (Analysis 1.8) and showed a significant reduction of
asymptomatic positive cultures for women in the nitrofurantoin
and close surveillance versus close surveillance alone. No symp-
tomatic recurrences were seen in women with more than 90%
clinic attendance rate.
Several secondary outcomes including stillbirth and maternal
deaths were not reported.
D I S C U S S I O N
Summary of main results
In this review we found no significant differences between a com-
bination of suppressive therapy with a daily dose of nitrofurantoin
and close surveillance and close surveillance alone in preventing
recurrent urinary tract infections (RUTI). Only sub-analyses in
womenwithmore than 90% follow-up show a decreased incidence
of asymptomatic bacteriuria (ASB) in women who received nitro-
furantoin and close surveillance compared with close surveillance
only. Since only one study was included no other interventions to
prevent RUTI in pregnant women were assessed.
Overall completeness and applicability of
evidence
The evidence for interventions preventing RUTI in pregnant
women is incomplete. This review included only one relatively
old (1983) trial involving 200 pregnant women with limited re-
porting of primary and secondary outcomes for both women and
infants. Due to lack of randomised controlled trials (RCTs), no
conclusions can be drawn regarding the optimal intervention to
prevent RUTI in women who are pregnant.
Quality of the evidence
The included trial hadmoderate to high risk of bias.GradePro soft-
ware was used to assess the quality of evidence for the main com-
parison ’nitrofurantoin and close surveillance versus close surveil-
lance alone’ for the outcomes listed above.The evidence was of
very low quality for all outcomes “recurrent pyelonephritis, RUTI
(cystitis), preterm birth (≤ 37 weeks), birthweight < 2500 (g),
birthweight (g), five-minute Apgar score less than seven, and mis-
carriages”. Downgrading of evidence was based on including one
small study with design limitations and imprecise results ’wide
confidence interval (CI) crossing the line of no effect’.
Potential biases in the review process
Data extraction and assessment of risk of the included study was
independently performed by two authors tominimise bias. A third
review author was contacted when consensus was not reached.
This review only includes one study therefore all conclusions need
to be considered with caution. We are not aware of other potential
biases in the review process.
Agreements and disagreements with other
studies or reviews
Following the results of this review, suppressive therapywith a daily
dose of nitrofurantoin and close surveillance has not been shown
to prevent RUTI compared with close surveillance alone. These
results are not consistent with a Cochrane review on antibiotics
to prevent urinary tract infection (UTI) in women who are not
pregnant, which showed that continuous antibiotic prophylaxis
for six to 12 months reduced the rate of UTI during prophylaxis
when compared with placebo (Albert 2008). In the latter review,
the authors did not compare antibiotics with non-pharmacological
interventions such as close surveillance. Moreover, more adverse
effects were seen in the antibiotic group including vaginal itching
and nausea. These side effects are not desirable in pregnant women
since both are already more frequent during pregnancy.
Little is known about the effect of close surveillance on preventing
RUTI. Lenke 1983 reported that all of the symptomatic recur-
rences occurred in patients who either had poor clinic attendance
and subsequent lack of follow-up urine cultures or were not treated
when gram-negative organisms (mainly uropathogens) were found
in their urine. These results explain that close surveillance itself al-
readymay have an effect on preventing RUTI in pregnant women.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This review found that daily dose of nitrofurantoin and close
surveillance was not more likely to prevent RUTI compared
with close surveillance alone. However, a significant reduction in
asymptomatic bacteriuria was found in women with a clinic atten-
dance rate of more than 90% and who received nitrofurantoin and
close surveillance. It is important to note that the results of this
review were based on only one small trial with limited reporting of
primary and secondary outcomes in both mother and child. Due
to the lack of randomised controlled trials no conclusions can be
drawn.
Implications for research
It is important to have a standard definition for RUTI in women
who are pregnant. Since pregnancy is a limited period during
which a UTI may be associated with increased risks for both
mother and baby, the definition for RUTI should be adapted
for pregnant women. A possible definition of RUTI in pregnant
women may be: at least one UTI during the current pregnancy or
either three UTI in the 12 months or two in six months before
onset of pregnancy.
Further large trials (with sufficient power) comparing differ-
ent pharmacological and non-pharmacological interventions are
needed to assess the optimal intervention to prevent RUTI in
women who are pregnant. Such trials should report on a broad
range outcomes for both women and infants. Given the signifi-
cant differences found in the greater than 90% follow-up group,
future trials should further asses the effects of close surveillance on
preventing RUTI in pregnant women
A C K N OW L E D G E M E N T S
Professor Ronald Stolk andDr Jan Jaap Erwich for their continued
advice and support.
The editorial team of the Cochrane Pregnancy and Childbirth
Group in Liverpool, UK.
We would like to thank Nasreen Aflaifel for her support in the
creation of the ’Summary of findings’ table for the 2015 update.
Nasreen Aflaifel’s work was financially supported by the UNDP/
UNFPA/UNICEF/WHO/World Bank Special Programme of Re-
search,Development andResearchTraining inHumanReproduc-
tion (HRP), Department of Reproductive Health and Research
(RHR), World Health Organization. The named authors alone
are responsible for the views expressed in this publication.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Preg-
nancy and Childbirth. The views and opinions expressed therein
are those of the authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, NHS or the Department
of Health.
R E F E R E N C E S
References to studies included in this review
Lenke 1983 {published data only}
∗ Lenke RR, Van Dorsten JP, Schifrin BS. Pyelonephritis
in pregnancy: a prospective randomized trial to prevent
recurrent disease evaluating suppressive therapy with
nitrofurantoin and close surveillance. American Journal of
Obstetrics and Gynecology 1983;146:953–7.
Van Dorsten JP, Lenke RR, Schifrin BS. Pyelonephritis
in pregnancy. The role of in-hospital management and




Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V,
Perrota C. Antibiotics for preventing recurrent urinary tract
infection in non-pregnant women. Cochrane Database
of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/
14651858.CD001209.pub2
Alreak 2002
Alraek T, Soedal LI, Fagerheim SU,Digranes A, Baerheim A.
Acupuncture treatment in the prevention of uncomplicated
recurrent lower urinary tract infections in adult women.
American Journal of Public Health 2002;92(10):1609–11.
MEDLINE: 1447293
Anderson 2007
Anderson BL, Simhan HN, Simons KM, Wiesenfeld HC.
Untreated asymptomatic group B streptococcal bacteriuria
early in pregnancy and chorioamnionitis at delivery.
American Journal of Obstetrics and Gynecology 2007;196(6):
524.e1–524.e5. MEDLINE: 17547879
Armstrong 2007
Armstrong J, Meis PJ. Clinical, family, and cost outcomes of
preterm births: an overview of the problem and prevention
opportunities. Journal of Clinical Outcomes Management
2007;14(10):547–53.
Aune 1998
Aune A, Alraek T, LiHua H, Baerheim A. Acupuncture in
the prophylaxis of recurrent lower urinary tract infection in
adult women. Scandinavian Journal of Primary Health Care
1998;16(1):37–9. MEDLINE: 9612877
Beerepoot 2011
Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de
Borgie CA, de Reijke TM, et al. Cranberries vs antibiotics to
14Interventions for preventing recurrent urinary tract infection during pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
prevent urinary tract infections: a randomized double-blind
noninferiority trial in premenopausal women. Archives
of Internal Medicine 2011;171(14):1270–8. MEDLINE:
21788542
Beerepoot 2012
Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de
Borgie CA, de Reijke TM, et al. Lactobacilli vs antibiotics
to prevent urinary tract Infections: a randomized, double-
blind, noninferiority trial in postmenopausal women.
Archives of Internal Medicine 2012;172(9):704–12.
Brown 1991
Brown MA. Urinary tract dilatation in pregnancy. American
Journal of Obstetrics and Gynecology 1991;164(2):642–3.
MEDLINE: 1992717
Bánhidy 2007
Bánhidy F, Acs N, Puhó EH, Czeizel AE. Pregnancy
complications and birth outcomes of pregnant women
with urinary tract infections and related drug treatments.
Scandinavian Journal of Infectious Diseases 2007;39(5):
390–7. MEDLINE: 17464860
Chen 2010
Chen YK, Chen SF, Li HC, Lin HC. No increased risk
of adverse pregnancy outcomes in women with urinary
tract infections: a nationwide population-based study. Acta
Obstetricia et Gynecologica Scandinavica 2010;89(7):882–8.
MEDLINE: 20583933
Clements 2007
Clements KM, Barfield WD, Ayadi MF, Wilber N.
Preterm birth-associated cost of early intervention services:
an analysis by gestational age. Pediatrics 2007;119(4):
e866–e874. MEDLINE: 17339387
Czaja 2007
Czaja CA, Stapleton AE, Yarova-Yarovaya Y, Stamm WE.
Phase I trial of a Lactobacillus crispatus vaginal suppository
for prevention of recurrent urinary tract infection in women.
Infectious Diseases in Obstetrics and Gynecology 2007;2007:
1–8. [DOI: 10.1155/2007/35387; MEDLINE: 18288237
Dimetry 2007
Dimetry SR, El-Tokhy HM, Abdo NM, Ebrahim MA,
Eissa M. Urinary tract infection and adverse outcome of
pregnancy. Journal of the Egyptian Public Health Association
2007;82(3-4):203–18. MEDLINE: 18410708
Dwyer 2002
Dwyer PL, O’Reilly M. Recurrent urinary tract infection
in the female. Current Opinion in Obstetrics & Gynecology
2002;14(5):537–43. MEDLINE: 12401984
Epp 2010
Epp A, Larochelle A, Lovatsis D, Walter JE, Easton W,
Farrell SA, et al. Recurrent urinary tract infection. Journal of
Obstetrics and Gynaecology Canada 2010;32(11):1082–101.
MEDLINE: 21176321
Foster 2008
Foster RT Sr. Uncomplicated urinary tract infections in
women. Obstetrics & Gynecology Clinics of North America
2008;35(2):235–48. MEDLINE: 18486839
Foxman 1990
Foxman B. Recurring urinary tract infection: incidence and
risk factors. American Journal of Public Health 1990;80(3):
331–3. MEDLINE: 2305919
Gilbert 2003
Gilbert WM, Nesbitt TS, Danielsen B. The cost of
prematurity: quantification by gestational age and birth
weight. Obstetrics & Gynecology 2003;102(3):488–92.
MEDLINE: 12962929
Gilstrap 1981
Gilstrap LC 3rd, Cunningham FG, Whalley PJ. Acute
pyelonephritis in pregnancy: a retrospective study. Obstetrics
& Gynecology 1981;57(4):409–13. MEDLINE: 7243084
Gilstrap 2001
Gilstrap LC 3rd, Ramin SM. Urinary tract infections
during pregnancy. Obstetrics and Gynecology Clinics of North
America 2001;28(3):581–91. MEDLINE: 11512502
Gopal 2007
Gopal M, Northington G, Arya L. Clinical symptoms
predictive of recurrent urinary tract infections. American
Journal of Obstetrics and Gynecology 2007;197(1):
74.e1–74.e4. MEDLINE: 17618765
GRADEpro 2014 [Computer program]
McMaster University. GRADEpro. [Computer program on
www.gradepro.org]. Version 2014. McMaster University,
2014.
Grenier 2000
Grenier N, Pariente JL, Trillaud H, Soussotte C, Douws
C. Dilatation of the collecting system during pregnancy:
physiologic vs obstructive dilatation. European Radiology
2000;10(2):271–9. MEDLINE: 10663756
Haider 2010
Haider G, Zehra N, Munir AA, Haider A. Risk factors of
urinary tract infection in pregnancy. Journal of Pakistan
Medical Association 2010;60(3):213–6. MEDLINE:
20225781
Harris 1974
Harris RE, Gilstrap LC 3rd. Prevention of recurrent
pyelonephritis during pregnancy. Obstetrics & Gynecology
1974;44(5):637–41. MEDLINE: 4419749
Harris 1981
Harris RE, Gilstrap LC 3rd. Cystitis during pregnancy: a
distinct clinical entity. Obstetrics & Gynecology 1981;57(5):
578–80.
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Hooton 1996
Hooton TM, Scholes D, Hughes JP, Winter C, Roberts
PL, Stapleton AE, et al. A prospective study of risk factors
for symptomatic urinary tract infection in young women.
New England Journal of Medicine 1996;335(7):468–74.
MEDLINE: 8672152
15Interventions for preventing recurrent urinary tract infection during pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hooton 2001
Hooton TM. Recurrent urinary tract infection in women.
International Journal of Antimicrobial Agents 2001;17(4):
259–68. MEDLINE: 11295405
Hooton 2010
Hooton TM. Recurrent urinary tract infections in women.
UpToDate (http://www.uptodate.com/home/about/
index.html) (accessed 2011) 2010:1–16.
Jepson 2012
Jepson RG, Williams G, Craig J. Cranberries for
preventing urinary tract infections. Cochrane Database
of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/
14651858.CD001321.pub5
Kodner 2010
Kodner CM, Thomas Gupton EK. Recurrent urinary tract
infections in women: diagnosis and management. American
Family Physician 2010;82(6):638–43. MEDLINE:
20842992
Lang 1996
Lang JM, Lieberman E, Cohen A. A comparison of risk
factors for preterm labor and term small-for-gestational-
age birth. Epidemiology 1996;7(4):369–76. MEDLINE:
8793362
Mabeck 1972
Mabeck CE. Treatment of uncomplicated urinary tract
infection in non-pregnant women. Postgraduate Medical
Journal 1972;48(556):69–75. MEDLINE: 4552445
Mann 2009
Mann JR, McDermott S, Gregg A, Gill TJ. Maternal
genitourinary infection and small for gestational age.
American Journal of Perinatology 2009;26(9):667–72.
MEDLINE: 19452428
Mazor-Dray 2009
Mazor-Dray E, Levy A, Schlaeffer F, Sheiner E. Maternal
urinary tract infection: is it independently associated with
adverse pregnancy outcome?. Journal of Maternal-Fetal
& Neonatal Medicine 2009;22(2):124–8. MEDLINE:
19085630
McCormick 2008
McCormick T, Ashe RG, Kearney PM. Urinary tract
infection in pregnancy. Obstetrician & Gynaecologist 2008;
10(3):156–62.
Olson 2003
Olson DM. The role of prostaglandins in the initiation of
parturition. Best Practice & Research Clinical Obstetrics &
Gynaecology 2003;17(5):717–30. MEDLINE: 12972010
Perotta 2008
Perotta C, Aznar M, Meija R, Albert X, Ng CW.
Oestrogens for preventing recurrent urinary tract infection
in postmenopausal women. Cochrane Database of
Systematic Reviews 2008, Issue 3. [DOI: 10.1002/
14651858.CD005131.pub2
Pfau 1992
Pfau A, Sacks TG. Effective prophylaxis for recurrent
urinary tract infections during pregnancy. Clinical Infectious
Diseases 1992;14(4):810–4. MEDLINE: 1576275
Reid 2003
Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman
D, Poehner R, et al. Oral use of Lactobacillus rhamnosus
GR-1 and L. fermentum RC-14 significantly alters vaginal
flora: randomized, placebo-controlled trial in 64 healthy
women. FEMS Immunology and Medical Microbiology 2003;
35(2):131–4. MEDLINE: 12628548
RevMan 2014 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Romero 1988
Romero R, Mazor M. Infection and preterm labor. Clinical
Obstetrics and Gynecology 1988;31(3):553–4. MEDLINE:
3066544
Savage 1967
Savage WE, Hajj SN, Kass EH. Demographic and
prognostic characteristics of bacteriuria in pregnancy.
Medicine 1967;46(5):385–407. MEDLINE: 4864339
Schieve 1994
Schieve LA, Handler A, Hershow R, Persky V, Davis F.
Urinary tract infection during pregnancy: its association
with maternal morbidity and perinatal outcome. American
Journal of Public Health 1994;84(3):405–10. MEDLINE:
8129056
Schnarr 2008
Schnarr J, Smaill F. Asymptomatic bacteriuria and
symptomatic urinary tract infections in pregnancy.
European Journal of Clinical Investigation 2008;38 Suppl 2:
50–7. MEDLINE: 18826482
Scholes 2000
Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta
K, Stamm WE. Risk factors for recurrent urinary tract
infection in young women. Journal of Infectious Diseases
2000;182(4):1177–82. [PUBMED: 10979915]
Schunemann 2009
Schunemann HJ. GRADE: from grading the evidence
to developing recommendations. A description of the
system and a proposal regarding the transferability of the
results of clinical research to clinical practice [GRADE:
Von der Evidenz zur Empfehlung. Beschreibung des
Systems und Losungsbeitrag zur Ubertragbarkeit von
Studienergebnissen]. Zeitschrift fur Evidenz, Fortbildung
und Qualitat im Gesundheitswesen 2009;103(6):391–400.
[PUBMED: 19839216]
Schwenger 2010
Schwenger EM, Tejani AM, Loewen PS. Probiotics for
preventing urinary tract infections in adults and children.
Cochrane Database of Systematic Reviews 2010, Issue 10.
[DOI: 10.1002/14651858.CD008772
Sheiner 2009
Sheiner E, Mazor-Drey E, Levy A. Asymptomatic bacteriuria
during pregnancy. Journal of Maternal-Fetal & Neonatal
Medicine 2009;22(5):423–7. MEDLINE: 19530000
16Interventions for preventing recurrent urinary tract infection during pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sobel 2014
Sobel JD, Kaye D. Urinary tract infections. In: Bennett
JE, Dolin R, Blaser MJ editor(s). Principles and Practice
of Infectious Disease. 8. Vol. 1, Philadephia: Churchill
Livingstone Elsevier, 2014:886–914.
U.S. Preventive Services Task Force 2008
U.S. Preventive Services Task Force. Screening for
asymptomatic bacteriuria in adults: U.S. Preventive Services
Task Force reaffirmation recommendation statement.
Annals of Internal Medicine 2008;149(1):43–7. MEDLINE:
18591636
Vazquez 2011
Vazquez JC, Abalos E. Treatments for symptomatic urinary
tract infections during pregnancy. Cochrane Database
of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/
14651858.CD002256.pub2
Wing 2008
Wing DA, Rumney PJ, Preslicka CW, Chung JH. Daily
cranberry juice for the prevention of asymptomatic
bacteriuria in pregnancy: a randomized, controlled
pilot study. Journal of Urology 2008;180(4):1367–72.
MEDLINE: 18707726
Zafiri 1989
Zafriri D, Ofek I, Adar R, Pocino M, Sharon N. Inhibitory
activity of cranberry juice on adherence of type 1 and type P
fimbriated Escherichia coli to eucaryotic cells. Antimicrobial
Agents and Chemotherapy 1989;33(1):92–8. MEDLINE:
2653218
References to other published versions of this review
Schneeberger 2012
Schneeberger C, Geerlings SE, Middleton P, Crowther
CA. Interventions for preventing recurrent urinary
tract infection during pregnancy. Cochrane Database
of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/
14651858.CD009279.pub2
∗ Indicates the major publication for the study
17Interventions for preventing recurrent urinary tract infection during pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Lenke 1983
Methods RCT.
Participants Number of pregnant women randomised: 200.
Inclusion criteria
• Pregnant.
• Admitted for pyelonephritis: CVA tenderness and in addition 2 of the following 3
criteria (1) temperature of ≥ 101oF, (2) pyuria (≥ 5 white blood cells per high power
field) or (3) bacteriuria (presence of any motile rods per high power field).
Exclusion criteria
• Prior history of pyelonephritis during the index pregnancy.
• Patients who delivered during the acute phase of pyelonephritis.
Setting: Los Angeles, USA.
Period: October 1979 - May 1981.
Definitions
• Recurrent UTI: significant dysuria or frequency in absence of fever or CVA
tenderness.
• Recurrent pyelonephritis: CVA tenderness and in addition 2 of the following 3
criteria (1) temperature of ≥ 101oF, (2) pyuria (≥ 5 white blood cells per high power
field) or (3) bacteriuria (presence of any motile rods per high power field).
• Positive culture: gram-negative organisms (≥103 colonies per mL) with growth of
no more than 1 other organism.
• Negative culture: no growth or < 103 gram-negative organisms per mL.
• Contaminated culture: gram-negative organisms present ≥103 per mL) with
concomitant growth of at least 2 other organisms.
Interventions Intervention group (n = 100): Nitrofurantoin 50 mg orally, 3 times daily, for the
remainder of the pregnancy plus close surveillance
Control group (n = 100): close surveillance only.
ALL WOMEN
Follow-up (close surveillance): all patients were followed in the special clinic every 2
weeks until the 36 weeks when they were seen weekly until delivery. At each visit a clean-
catch, mid voided urine was obtained for a routine culture and nitrite testing. When
culture results were positive, attempts were made to reach patients to schedule a return
appointment within 1 week
Treatment: irrespective of group, patients received a short course of antibiotics in clinic
under 3 circumstances:
1. if the patient’s last culture (on suppression in the treated group) was positive;
2. if the nitrite test was positive;
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• Clinic attendance > 90%.
• Asymptomatic bacteriuria (ASB) in > 90% attendance group.
Infants
• Premature birth (< 37 weeks).
• Birthweight (g).
• Birthweight ≤ 2500 (g).
• 5-minute Apgar score < 7.
• 1-minute Apgar score < 7.
• Placental weight (g).
• Head circumference (cm).
• Body length (cm).
• Post mature (> 42 weeks).
Notes • Funding: supported in part by Ariel Kaare Rosholt Weathers-Lowin Medical
Research Foundation and National Institute of Health grant HD07086-05.
• Table shows birthweight ≥ 2500 (g). We think this should be < 2500 (g) and have
entered it accordingly.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random number tables.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participant: no blinding.
Clinician: no blinding.
Describe:
“the control group received no pills”
“ the doctors responsible for patient care were aware of whether
the patient was in the treated or control group”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Low for culture results.
Low for pregnancy outcomes.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Lost to follow-up:
• 18/100 nitrofurantoin and close surveillance group;
• 15/100 close surveillance group.
No reasons given.
Selective reporting (reporting bias) High risk Overall, very few pregnancy outcomes were measured. “observa-
tion period ended at the time of delivery, as logistics prevented
longer follow-up”
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Lenke 1983 (Continued)
Other bias Low risk No major baseline differences.
CVA: costovertebral angle
mL: millilitre
RCT: randomised controlled trials
UTI: urinary tract infection
20Interventions for preventing recurrent urinary tract infection during pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Nitrofurantoin and close surveillance versus close surveillance alone




participants Statistical method Effect size
1 Recurrent pyelonephritis 1 167 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.31, 2.53]
2 Recurrent UTI (cystitis) 1 167 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.06, 1.38]
3 Preterm birth (< 37 weeks) 1 147 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.42, 3.35]
4 Birthweight < 2500 (g) (not
prespecified)
1 147 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.53, 7.80]
5 Birthweight (g) 1 147 Mean Difference (IV, Fixed, 95% CI) -113.0 [-327.20,
101.20]
6 Five-minute Apgar score < seven 1 147 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.19, 21.87]
7 Miscarriages 1 167 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [0.33, 29.29]
8 Asymptomatic bacteriuria in
women with 90% clinical
attendance
1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.34, 0.89]
Analysis 1.1. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
1 Recurrent pyelonephritis.
Review: Interventions for preventing recurrent urinary tract infection during pregnancy
Comparison: 1 Nitrofurantoin and close surveillance versus close surveillance alone




lance Surveillance alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lenke 1983 6/82 7/85 100.0 % 0.89 [ 0.31, 2.53 ]
Total (95% CI) 82 85 100.0 % 0.89 [ 0.31, 2.53 ]
Total events: 6 (Nitro and surveillance), 7 (Surveillance alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Nitro and surveillance Surveillance alone
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Analysis 1.2. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
2 Recurrent UTI (cystitis).
Review: Interventions for preventing recurrent urinary tract infection during pregnancy
Comparison: 1 Nitrofurantoin and close surveillance versus close surveillance alone




lance Surveillance alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lenke 1983 2/82 7/85 100.0 % 0.30 [ 0.06, 1.38 ]
Total (95% CI) 82 85 100.0 % 0.30 [ 0.06, 1.38 ]
Total events: 2 (Nitro and surveillance), 7 (Surveillance alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Nitro and surveillance Surveillance alone
Analysis 1.3. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
3 Preterm birth (< 37 weeks).
Review: Interventions for preventing recurrent urinary tract infection during pregnancy
Comparison: 1 Nitrofurantoin and close surveillance versus close surveillance alone




lance Surveillance alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lenke 1983 7/73 6/74 100.0 % 1.18 [ 0.42, 3.35 ]
Total (95% CI) 73 74 100.0 % 1.18 [ 0.42, 3.35 ]
Total events: 7 (Nitro and surveillance), 6 (Surveillance alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Nitro and surveillance Surveillance alone
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Analysis 1.4. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
4 Birthweight < 2500 (g) (not prespecified).
Review: Interventions for preventing recurrent urinary tract infection during pregnancy
Comparison: 1 Nitrofurantoin and close surveillance versus close surveillance alone
Outcome: 4 Birthweight < 2500 (g) (not prespecified)
Study or subgroup Nitrofurantoin Close surveillance Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lenke 1983 6/73 3/74 100.0 % 2.03 [ 0.53, 7.80 ]
Total (95% CI) 73 74 100.0 % 2.03 [ 0.53, 7.80 ]
Total events: 6 (Nitrofurantoin), 3 (Close surveillance)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Nitro and surveillance Surveillance alone
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Analysis 1.5. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
5 Birthweight (g).
Review: Interventions for preventing recurrent urinary tract infection during pregnancy
Comparison: 1 Nitrofurantoin and close surveillance versus close surveillance alone









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lenke 1983 71 3232 (758.35) 76 3345 (540.5) 100.0 % -113.00 [ -327.20, 101.20 ]
Total (95% CI) 71 76 100.0 % -113.00 [ -327.20, 101.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Nitro and surveillance Surveillance alone
Analysis 1.6. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
6 Five-minute Apgar score < seven.
Review: Interventions for preventing recurrent urinary tract infection during pregnancy
Comparison: 1 Nitrofurantoin and close surveillance versus close surveillance alone




lance Surveillance alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lenke 1983 2/73 1/74 100.0 % 2.03 [ 0.19, 21.87 ]
Total (95% CI) 73 74 100.0 % 2.03 [ 0.19, 21.87 ]
Total events: 2 (Nitro and surveillance), 1 (Surveillance alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Nitro and surveillance Surveillance alone
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Analysis 1.7. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
7 Miscarriages.
Review: Interventions for preventing recurrent urinary tract infection during pregnancy





lance Surveillance alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lenke 1983 3/82 1/85 100.0 % 3.11 [ 0.33, 29.29 ]
Total (95% CI) 82 85 100.0 % 3.11 [ 0.33, 29.29 ]
Total events: 3 (Nitro and surveillance), 1 (Surveillance alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Nitro and surveillance Surveillance alone
Analysis 1.8. Comparison 1 Nitrofurantoin and close surveillance versus close surveillance alone, Outcome
8 Asymptomatic bacteriuria in women with 90% clinical attendance.
Review: Interventions for preventing recurrent urinary tract infection during pregnancy
Comparison: 1 Nitrofurantoin and close surveillance versus close surveillance alone




lance Surveillance alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lenke 1983 14/43 35/59 100.0 % 0.55 [ 0.34, 0.89 ]
Total (95% CI) 43 59 100.0 % 0.55 [ 0.34, 0.89 ]
Total events: 14 (Nitro and surveillance), 35 (Surveillance alone)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Nitro and surveillance Surveillance alone
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A P P E N D I C E S
Appendix 1. Methods to be used in future updates
The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.
Selection of studies
Two review authors will independently assess for inclusion all the potential studies identified as a result of the search strategy. We will
resolve any disagreement through discussion or, if required, we will consult a third review author.
Data extraction and management
We will design a form to extract data. For eligible studies, two review authors will extract the data using the agreed form. We will
resolve discrepancies through discussion or, if required, we will consult the third review author. We will enter data into ReviewManager
software (RevMan 2014) and check for accuracy. When information regarding any of the above is unclear, we plan to contact authors
of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Any disagreement will be resolved by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible selection bias)
We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We will describe for each included study the method used to conceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);
• unclear risk of bias.
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(3.1) Blinding of participants and personnel (checking for possible performance bias)
We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which
intervention a participant received. We will consider that studies were at low risk of bias if they were blinded, or if we judged that the
lack of blinding unlikely to affect results. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible detection bias)
We will describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a
participant received. We will assess blinding separately for different outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing
data were balanced across groups or were related to outcomes. Where sufficient information is reported, or could have been supplied
by the trial authors, we plan to re-include missing data in the analyses which we undertake.
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial
departure of intervention received from that assigned at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-specified outcomes and all expected outcomes of interest to the review
have been reported);
• high risk of bias (where not all the study’s pre-specified outcomes have been reported; one or more reported primary outcomes
were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)
We will describe for each included study any important concerns we had about other possible sources of bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies were at high risk of bias, according to the criteria given in the Handbook
(Higgins 2011). With reference to (1) to (6) above, we plan to assess the likely magnitude and direction of the bias and whether we
considered it is likely to impact on the findings. We will explore the impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
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Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk ratio with 95% confidence intervals.
Continuous data
Wewill use the mean difference if outcomes were measured in the same way between trials. We will use the standardised mean difference
to combine trials that measured the same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
We will include cluster-randomised trials in the analyses along with individually-randomised trials. We will adjust either their sample
sizes or standard errors using the methods described in the Handbook [Section 16.3.4 or 16.3.6] using an estimate of the intracluster
correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we
use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We will
consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction
between the effect of intervention and the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
It is unlikely that cross-over designs will be a valid study design for Pregnancy and Childbirth reviews and so, if identified, we will
exclude them.
Dealing with missing data
For included studies, we will note levels of attrition. If more eligible studies are included, we will explore the impact of including studies
with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.
For all outcomes, we will carry out analyses, as far as possible, on an intention-to-treat basis, that is, we will attempt to include all
participants randomised to each group in the analyses. The denominator for each outcome in each trial will be the number randomised
minus any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We will regard heterogeneity as
substantial if an I² is greater than 30% and either a Tau² is greater than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity. If we identify substantial heterogeneity (above 30%), we plan to explore it by pre-specified subgroup analysis.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots.
We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses
to investigate it.
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Data synthesis
We will carry out statistical analysis using the Review Manager software (RevMan 2014). We will use fixed-effect meta-analysis for
combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials
are examining the same intervention, and the trials’ populations and methods are judged sufficiently similar.
If there is clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical
heterogeneity is detected, we will use random-effects meta-analysis to produce an overall summary, if an average treatment effect across
trials is considered clinically meaningful. The random-effects summary will be treated as the average range of possible treatment effects
and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically
meaningful, we will not combine trials. If we used random-effects analyses, the results will be presented as the average treatment effect
with 95% confidence intervals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether
an overall summary is meaningful, and if it is, we will use random-effects analysis to produce it.
We will carry out the following subgroup analyses.
1. Type of bacteriuria: asymptomatic bacteriuria (without symptoms) versus UTI (with symptoms) versus pyelonephritis (requiring
hospitalisation). We wish to test whether results differ when UTI is variously defined, according to the severity of the condition and
the presence of symptoms.
2. Definition of RUTI: history of RUTI before pregnancy versus no history of RUTI before pregnancy. We wish to test whether
results differ when women already have a history of RUTI before their pregnancy.
3. Gestational age at which the intervention was started before 20 weeks versus equal to or greater than 20 weeks. We wish to test
whether the effects of the interventions are different according to the stage of pregnancy in which they were started.
4. Types of interventions: pharmacological versus non-pharmacological. We wish to test whether the results differ between
pharmacological and non-pharmacological interventions.
The following outcomes will be used in subgroup analyses.
Maternal
• Recurrent urinary tract infections (RUTI) before birth (variously defined)
• Preterm birth (less than 37 weeks)
Infant
• Small-for-gestational age
• Total mortality (including stillbirth and babies born alive who die prior to primary hospital discharge)
We will assess subgroup differences by interaction tests available within RevMan (RevMan 2014).We will report the results of subgroup
analyses quoting the Chi² statistic and P value, and the interaction test I² value.
Sensitivity analysis
We plan to carry out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates,
or both, with poor quality studies being excluded from the analyses in order to assess whether this makes any difference to the overall
result.
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WH A T ’ S N E W
Date Event Description
9 April 2015 New citation required but conclusions have not changed Review updated.
9 April 2015 New search has been performed Search updated. No new reports identified.
A ’Summary of findings’ table has been incorporated.
Background updated.
C O N T R I B U T I O N S O F A U T H O R S
The protocol was drafted jointly by Caroline Schneeberger, Suzanne Geerlings, Caroline A Crowther and PhilippaMiddleton. Caroline
Schneeberger is guarantor for the review.
For the 2015 update, all authors were involved
D E C L A R A T I O N S O F I N T E R E S T
Caroline Schneeberger, Caroline A Crowther and Philippa Middleton: none known.
Suzanne E Geerlings is project leader of the following study: Non-antibiotic versus antibiotic prophylaxis for recurrent urinary tract
infections (NAPRUTI)-study. Trial Number: ISRCTN50717094. This study did not include pregnant women. For this study, placebo
lactobacilli capsules were donated by Chr Hansen, Denmark. Cranberry capsules and placebo capsules for the study were provided by
Springfield Nutraceuticals, Oud Beijerland, the Netherlands.
S O U R C E S O F S U P P O R T
Internal sources
• ARCH, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Australia.
• University Medical Center Groningen (UMCG), Netherlands.
External sources
• Australian Department of Health and Ageing, Australia.
• UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human
Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization, Switzerland.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not seek unpublished trials by contacting experts in the field or scan the Internet and abstracts submitted to major international
congresses as stated in our published protocol. We added birthweight < 2500 (g) to the list of outcomes since this is commonly used
primary outcome especially in older studies.
A ’Summary of findings’ table was added for this 2015 update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Secondary Prevention; Anti-Infective Agents, Urinary [∗therapeutic use]; Bacteriuria [prevention & control]; Nitrofurantoin
[∗therapeutic use]; Pregnancy Complications, Infectious [∗prevention & control]; Randomized Controlled Trials as Topic; Recurrence;
Urinary Tract Infections [∗prevention & control]; Watchful Waiting
MeSH check words
Female; Humans; Pregnancy
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